Press releaseBusiness Wire
Vyne Therapeutics
YARW · NASDAQ
$20.21+$0.23 (+1.15%)TodayMarket closed ·
Prev close $19.98
Latest news
- Press releaseBusiness Wire
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
- Press releaseBusiness Wire
Yarrow Bioscience Announces Proposed Underwritten Public Offering
- Press releaseBusiness Wire
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
- Press releaseBusiness Wire
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.